Status:

ACTIVE_NOT_RECRUITING

Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older

Lead Sponsor:

Sanofi Pasteur, a Sanofi Company

Conditions:

Respiratory Syncytial Virus Infection

Metapneumovirus Infection

Eligibility:

All Genders

60+ years

Phase:

PHASE1

Brief Summary

The purpose of this phase 1 study is to evaluate whether the vaccine is safe and can help the body to develop germ fighting agents called "antibodies" (immunogenicity) against the respiratory syncytia...

Detailed Description

The study duration will be up to approximately 12 months minus the screening period.

Eligibility Criteria

Inclusion

  • Aged 60 years or older on the day of inclusion (means from the means from the day of the 60th birthday).
  • Informed consent form (ICF) has been signed and dated
  • A female participant is eligible to participate if she is of non-childbearing potential. To be considered of non-childbearing potential, a female must be postmenopausal for at least 1 year, or surgically sterile.

Exclusion

  • Participants are excluded from the study if any of the following criteria apply:
  • Any condition which, in the opinion of the Investigator, might interfere with the evaluation of the study objectives.
  • Note: The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Key Trial Info

Start Date :

September 17 2024

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 5 2026

Estimated Enrollment :

390 Patients enrolled

Trial Details

Trial ID

NCT06604767

Start Date

September 17 2024

End Date

March 5 2026

Last Update

April 4 2025

Active Locations (8)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (8 locations)

1

Investigational Site Number : 0360006

Blacktown, New South Wales, Australia, 2148

2

Investigational Site Number : 0360001

Botany, New South Wales, Australia, 2019

3

Investigational Site Number : 0360009

Brookvale, New South Wales, Australia, 2100

4

Investigational Site Number : 0360005

Kanwal, New South Wales, Australia, 2259

Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older | DecenTrialz